Formulary and logistical considerations with the introduction of cell-based gene therapies
- At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
- Type: Presentation
- By: KIRSA, Suzanne (Monash Health, Australia)
Gene Therapies are being commercialised across the world. These treatments are not conventional therapeutic products. Regulatory approvals differ across countries. Hospitals may choose approval and governance processes that by-pass the Pharmacy or Therapeutics committees unless Pharmacists actively pursue involvement. Toxicity profiles will.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.